All Stories

  1. Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma

    Article • Leukemia & Lymphoma, April 2019, Taylor & Francis

    Michelle Fanale, Thao Vo